Why is the pharmaceutical industry investing in targeted therapies? The emergence of “premium pharma” Recent decades have witnessed a major transformation in biomedical knowledge production, framed as the rise of personalized, precision, or stratified …

New paper w/Paul Martin & Jin Ding: “Why is the pharmaceutical industry investing in targeted therapies? The emergence of “premium pharma" | How #orphandrugs #ATMPs #TargetedTherapies reshape #BioPharmaInnovation #HTA sciencedirect.com/science/article/pii/S0277953625012195 @sheffielduni.bsky.social

Evidence silos slow progress. Lumanity’s Evidence Navigator™ unites Medical, Regulatory, HEOR & Commercial to align needs, close gaps & plan smarter. Break down barriers & boost impact: buff.ly/Wby8nzP #EvidencePlanning #IEGP #BiopharmaInnovation

March Biosciences presents CAR T cell therapy progress at CPRIT advisory committee meeting March Biosciences outlines advancements in T cell lymphoma therapy during CPRIT meeting.

CPRIT's recent meeting revealed the resilience of the biopharma sector amid challenges, showcasing groundbreaking advancements in CAR T cell therapy that could change cancer treatment forever.

Click to read more!

#TX #CitizenPortal #BiopharmaInnovation #TexasCancerResearch #FundingChallenges

#CellTherapy #RegenerativeMedicine #Immunotherapy #AdvancedTherapies #CAR_TCells #GeneTherapy #StemCellResearch #CellAndGeneTherapy #InnovativeMedicine #NextGenTherapies #PrecisionMedicine #Biotechnology #CancerImmunotherapy #TCellTherapy #GeneEditing #PersonalizedMedicine #BiopharmaInnovation